Sandoz Fills Pipeline Gap With Samsung Bioepis’ Ustekinumab

Strikes Deal In Multiple Global Markets For SB17 Biosimilar Rival To Stelara

 
• By Dave Wallace

Sandoz has filled a gap in its biosimilars pipeline by in-licensing Samsung Bioepis’ SB17 ustekinumab biosimilar to Stelara, for commercialization in multiple global markets.

Hand placing jigsaw puzzle piece into gap
Another piece of Sandoz’s biosimilars portfolio has fallen into place • Source: Shutterstock

More from Deals

More from Business